乌司他丁用于临床常见急危重症的专家共识

• 作者： 《乌司他丁用于临床常见急危重症的专家共识》专家组
• 作者单位：
• 提交时间：2023-06-07

摘要: 乌司他丁具有抑制蛋白水解酶、调控炎症反应等作用，目前主要应用于急性胰腺炎，但也被应用于休克、脓毒症、重症肺炎、急性呼吸窘迫综合征、多种急性中毒、重症中暑、重度烧伤、严重创伤等其他临床常见急危重症及心搏骤停患者，而且已被临床常见急危重症诊治相关的多个指南/专家共识推荐。然而，目前关于乌司他丁的适应证及其用法、用量等尚缺乏统一意见。因此，为推动乌司他丁的规范化应用，《乌司他丁用于临床常见急危重症的专家共识》专家组针对乌司他丁的作用机制、药代动力学、适应证及在常见急危重症中的应用方法等进行了归纳、总结，以期为乌司他丁在临床工作中的合理应用提供参考。

Abstract: Ulinastatin is mainly applied in the treatment of acute pancreatitis，but also in other common clinical critical illnesses such as shock，sepsis，evere pneumonia，cute respiratory distress syndrome，several acute poisoning，severe heat stroke，severe burns，severe trauma，and patients with sudden cardiac arrest for its roles in proteolytic enzymes inhibition and inflammatory responses regulation，which has been recommended by several guidelines/expert consensus on the diagnose and treatment of common clinical critical illness. However，there is currently a lack of consensus on the rational use of ulinastatin in terms of indications，usage，dosage，and others. Therefore，in order to promote the standardized application of ulinastatin，the expert group of expert consensus on the application of ulinastatin in common clinical critical illness summarized the mechanism， pharmacokinetics，indications of ulinastatin and its application methods in the treatment of common clinical critical illness，in order to provide a reference for the rational application of ulinastatin in clinical practice.

• 分类： 医学、药学 >> 临床医学
• 引用： ChinaXiv:202306.00058 (或此版本 ChinaXiv:202306.00058V1)
  DOI:10.12114/j.issn.1007-9572.2023.0157
  CSTR:32003.36.ChinaXiv.202306.00058.V1
• 推荐引用方式： 《乌司他丁用于临床常见急危重症的专家共识》专家组.(2023).乌司他丁用于临床常见急危重症的专家共识.中国全科医学.doi:10.12114/j.issn.1007-9572.2023.0157 (点此复制)